Shares of CTI BioPharma Corp (NASDAQ:CTIC) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.85 and traded as high as $0.75. CTI BioPharma shares last traded at $0.74, with a volume of 21,301 shares traded.

The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.18. The stock has a 50-day simple moving average of $0.85.

CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. The business had revenue of $0.64 million for the quarter. CTI BioPharma had a negative return on equity of 67.97% and a negative net margin of 224.53%.

A number of hedge funds have recently modified their holdings of the stock. Deutsche Bank AG raised its holdings in CTI BioPharma by 220.7% during the 4th quarter. Deutsche Bank AG now owns 367,717 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 253,060 shares during the period. Two Sigma Advisers LP raised its holdings in CTI BioPharma by 14.0% during the 4th quarter. Two Sigma Advisers LP now owns 115,483 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 14,200 shares during the period. Finally, Rhumbline Advisers raised its holdings in CTI BioPharma by 45.4% during the 4th quarter. Rhumbline Advisers now owns 66,079 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 20,630 shares during the period. Institutional investors and hedge funds own 52.76% of the company’s stock.

CTI BioPharma Company Profile (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Read More: What does earnings per share mean?

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.